Table 3. Uni- and multivariate analyses of time to recurrence (TTR).
|
Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| Median OS (months) | 95% CI | P value | HR | 95% CI | P value | |
| Sex | 0.72 | |||||
| Female | 22 | 19.8–24.19 | — | — | — | |
| Male | 21 | 18.71–23.29 | ||||
| Mutation | 0.01 | |||||
| WT | 24 | 21.69–26.3 | — | — | — | |
| EGFR | 24 | 16.37–31.63 | ||||
| KRAS | 19 | 17.19–20.8 | ||||
| Mutation | <0.0001 | |||||
| KRAS G12V | 15 | 13.46–16.54 | 0.67 | 0.48–0.92 | 0.01 | |
| Non-KRAS G12V | 24 | 22.71–25.29 | ||||
| Nodal status | 0.77 | |||||
| N0 | 21 | 18.08–23.92 | — | — | — | |
| N+ | 22 | 19.97–24.03 | ||||
| pT | 0.09 | |||||
| 1 | 21 | 18.3–23.7 | — | — | 0.08 | |
| 2 | 24 | 21.78–26.22 | ||||
| 3 | 19 | 15.64–22.36 | ||||
| 4 | 19 | 14–23.99 | ||||
| Angioinvasion | 0.01 | |||||
| Yes | 18 | 16.11–19.88 | — | — | 0.38 | |
| No | 24 | 22.56–25.44 | ||||
| Smoking habit | 0.11 | |||||
| Never | 24 | 14.14–33.86 | — | — | 0.59 | |
| Past | 21 | 17.24–24.76 | ||||
| Current | 21 | 18.94–23.06 | ||||
| Neo-adjuvant treatment | 0.26 | |||||
| Yes | 21 | 18.32–23.68 | — | — | — | |
| No | 22 | 19.98–24.01 | ||||
| Type of neo-adjuvant treatment | 0.04 | |||||
| Chemo. | 19 | 16.11–21.89 | — | — | 0.57 | |
| RT chemo. | 25 | 20.97–29.02 | ||||
| Adjuvant treatment | 0.9 | |||||
| Yes | 22 | 19.59–24.41 | — | — | — | |
| No | 21 | 18.42–23.58 | ||||
| Type of adjuvant treatment | 0.4 | |||||
| RT | 34 | 21.99–46 | — | — | — | |
| Chemo. | 21 | 18.38–23.62 | ||||
| RT chemo. | 25 | 19.37–30.63 | ||||
| CCI | 0.56 | |||||
| 0 | 22 | 16.91–27.09 | — | — | — | |
| 1 | 24 | 21.88–26.12 | ||||
| 2 | 21 | 18.38–23.62 | ||||
| 3 | 19 | 15.95–22.05 | ||||
| Type of resection | 0.34 | |||||
| Seg. | 24 | 15.84–32.15 | — | — | — | |
| Lob. | 21 | 18.93–23.06 | ||||
| Bi-lob. | 17 | |||||
| Pneum. | 25 | 18.06–31.94 | ||||
| Skip N | 0.002 | |||||
| Yes | 19 | 13.87–24.13 | — | — | 0.19 | |
| No | 25 | 16.05–33.94 | ||||
| Microscopic N | 0.12 | |||||
| Yes | 24 | 19.3–28.69 | — | — | 0.23 | |
| No | 18 | 16.16–19.83 | ||||
| Number of N2 stations involved | 0.45 | |||||
| 1 | 25 | 21.78–28.22 | — | — | — | |
| 2 | 25 | 15.81–34.19 | ||||
| R0 | 21 | 19.38–22.62 | 0.51 | — | — | — |
| R1 | 34 | 7.7–60.29 | ||||
Abbreviations: Bi-lob=bi-lobectomy; CCI=Charlson comorbidity index; chemo.=chemotherapy; CI=confidence interval; HR=hazard ratio; Lob=lobectomy; NR=not reached; OS=overall survival; Pneum=pneumonectomy; RT=radiotherapy; Seg=segmentectomy; WT=wild type.
Because KRAS G12V and mutational status correlated, only KRAS G12V status was entered in the multivariate model. Non-KRAS G12V included wild-type, EGFR mutants and KRAS non-G12V patients.